Henry Joseph Michtalik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henry Joseph Michtalik has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Eishita Pal
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publications - Jean Christophe Rusatira
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publications - Alain K. Koffi
Johns Hopkins Bloomberg School of Public Health
1 shared publication - Ayesha Khan
Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publication - Lev Kubiak
Pfizer
1 shared publication - Lubna Merchant
Pfizer
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by BMJ in BMJ Connections Oncology
- Vol. 3 (1) , e000069
Healthcare providers’ knowledge gaps and educational needs in addressing substandard and falsified oncology drugs: a scoping review
Introduction: Substandard and falsified (SF) drugs are an increasingly widespread threat to global health. Expensive medicines that are prone to shortages, such as cancer therapies, tend to be a target of counterfeiters due to their high profit potential. There are concerns that healthcare providers (HCPs) lack knowledge of SF drug threats and how to identify and report suspicious drugs. We conducted this scoping review to map evidence on oncology HCPs’ awareness, knowledge and educational needs regarding SF oncology drugs. Specifically, we examined HCPs’ awareness of SF prevalence, confidence in counselling patients to prevent exposure and ability to report suspected cases to regulatory authorities. Research design and methods: This scoping review was conducted using the Arksey and O’Malley scoping review framework. We searched PubMed and Embase databases through 14 December 2024 using keywords on the topics of: (1) SF drugs in oncology, (2) challenges and supply chain integrity specific to oncology drugs and antineoplastics and (3) successful education and training models for HCPs working in oncology. Thematic analysis and narrative synthesis were conducted on the included papers. Results: We identified 50 studies from 22 countries for our thematic analysis. Drug shortages, affordability and the rise of e-pharmacy were found to contribute to the propagation of SF oncology drugs globally. HCP awareness of SF drugs was generally low. Successful drug safety education interventions predominantly focused on pharmacovigilance and adverse drug reaction reporting rather than identifying SF drugs and counselling patients on safe drug purchasing practices. Conclusions: SF oncology drugs are a global public health issue and HCPs generally lack adequate awareness of this problem. Educational interventions should be targeted at improving oncology HCPs’ knowledge of SF drug prevalence, and their ability to both identify and report SF drugs to the proper authorities and counsel patients on how to purchase drugs safely.
- 16 January 2026
- Published by BMJ in BMJ Connections Oncology
- Vol. 3 (1) , e000069
Open AccessHealthcare providers’ knowledge gaps and educational needs in addressing substandard and falsified oncology drugs: a scoping review
Introduction: Substandard and falsified (SF) drugs are an increasingly widespread threat to global health. Expensive medicines that are prone to shortages, such as cancer therapies, tend to be a target of counterfeiters due to their high profit potential. There are concerns that healthcare providers (HCPs) lack knowledge of SF drug threats and how to identify and report suspicious drugs. We conducted this scoping review to map evidence on oncology HCPs’ awareness, knowledge and educational needs regarding SF oncology drugs. Specifically, we examined HCPs’ awareness of SF prevalence, confidence in counselling patients to prevent exposure and ability to report suspected cases to regulatory authorities. Research design and methods: This scoping review was conducted using the Arksey and O’Malley scoping review framework. We searched PubMed and Embase databases through 14 December 2024 using keywords on the topics of: (1) SF drugs in oncology, (2) challenges and supply chain integrity specific to oncology drugs and antineoplastics and (3) successful education and training models for HCPs working in oncology. Thematic analysis and narrative synthesis were conducted on the included papers. Results: We identified 50 studies from 22 countries for our thematic analysis. Drug shortages, affordability and the rise of e-pharmacy were found to contribute to the propagation of SF oncology drugs globally. HCP awareness of SF drugs was generally low. Successful drug safety education interventions predominantly focused on pharmacovigilance and adverse drug reaction reporting rather than identifying SF drugs and counselling patients on safe drug purchasing practices. Conclusions: SF oncology drugs are a global public health issue and HCPs generally lack adequate awareness of this problem. Educational interventions should be targeted at improving oncology HCPs’ knowledge of SF drug prevalence, and their ability to both identify and report SF drugs to the proper authorities and counsel patients on how to purchase drugs safely.
- Open Access
- 12 September 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1)
Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review
The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public. A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature. A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public. This review highlights the need for innovative, targeted strategies – such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns – to bridge the gap between awareness and effective practice. Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today’s rapidly evolving digital landscape.
- 12 September 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1)
Open AccessAssessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review
The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public. A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature. A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public. This review highlights the need for innovative, targeted strategies – such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns – to bridge the gap between awareness and effective practice. Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today’s rapidly evolving digital landscape.